FAIR PRICING FOR MEDICINES

That this House notes with deep concern that the issue of excessively high medicine prices and systemic lack of transparency in the Research & Development (R&D) system is a global crisis; further notes that the second Fair Pricing Forum will take place in April 2019 presenting a critical opportunity for stakeholders to discuss how to respond to arbitrary priced medicines and define what is a fair price for medicines; acknowledges that different people will have different understandings of what is fair price; believes that a definition of fairness must prioritise access to medicines and transparency of R&D outlays and price-setting; and calls on the UK Government and other World Health Organisation member states to support Italy’s draft resolution entitled, Improving the transparency of markets for drugs, vaccines and other health-related technologies that will be discussed at the 72nd World Health Assembly.